Oluchukwu Oluoha, MD (@oluoha) profile picture

Oluchukwu Oluoha, MD

@oluoha

Medical Oncologist/Hematologist @TexasOncology

 United States
bit.ly/OluchukwuOluoha
Joined June 2011
  • Tweets140
  • Following218
  • Followers153
4Media
Photo by Oluchukwu Oluoha, MD (@oluoha)Photo by Oluchukwu Oluoha, MD (@oluoha)
For Squamous Cancers, the Streetlamps Shine on Occasional Keys, Most Baskets Are Empty, and the Umbrellas Cannot Keep Us Dry: A Call for New Models in Precision Oncology | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…

For Squamous Cancers, the Streetlamps Shine on Occasional Keys, Most Baskets Are Empty, and the...

ascopubs.org
2
518
Oluchukwu Oluoha, MD retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJM6 Nov 2025
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer (SUPREMO phase 3 trial) nej.md/3Jxd3sI Editorial: Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer nej.md/49BPQQt #Oncology
Kaplan–Meier estimates of unadjusted overall survival (intention-to-treat population).

ALT Kaplan–Meier estimates of unadjusted overall survival (intention-to-treat population).

Unadjusted Kaplan–Meier estimates of chest-wall recurrence (Panel A), locoregional recurrence (Panel B), distant metastasis–free survival (Panel C), and disease-free survival (Panel D).

ALT Unadjusted Kaplan–Meier estimates of chest-wall recurrence (Panel A), locoregional recurrence (Panel B), distant metastasis–free survival (Panel C), and disease-free survival (Panel D).

1
6
20
12,980
Oluchukwu Oluoha, MD retweeted
CURE Today (@cure_today) profile picture
CURE Today
@cure_today6 Nov 2025
The FDA approved Darzalex Faspro for the treatment of adults with high-risk smoldering multiple myeloma. #MultipleMyeloma Read more here: hubs.li/Q03S55xq0
Image from CURE Today (@cure_today)
2
3
212
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic...

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic...

PURPOSEDatopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2–directed antibody-drug conjugate with a highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II...

ascopubs.org
121
Zolbetuximab Plus Chemotherapy Wins EU Approval for Advanced CLDN18.2+ Gastric/GEJ Cancer onclive.com/view/zolbetuxima…

Zolbetuximab Plus Chemotherapy Wins EU Approval for Advanced CLDN18.2+ Gastric/GEJ Cancer | OncLive

The European Commission has approved frontline zolbetuximab plus chemotherapy for advanced, CLDN18.2-positive gastric and GEJ cancer.

onclive.com
170
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia | NEJM

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia | NEJM

Patients with newly diagnosed chronic myeloid leukemia (CML) need long-term therapy with high efficacy and safety. Asciminib, a BCR::ABL1 inhibitor specifically targeting the ABL myristoyl pocket, ...

nejm.org
1
119
Oluchukwu Oluoha, MD retweeted
Yakup Ergün (@dr_yakupergun) profile picture
Yakup Ergün
@dr_yakupergun15 Sep 2024
#ESMO24 Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2 🔍One dose of ipilimumab and two doses of nivolumab prior to surgery, 64% had cT4 tumors. 3-year DFS➡️💯% Presented by @MyriamChalabi
Image from Yakup Ergün (@dr_yakupergun)
3
38
5
120
12,246
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee ow.ly/XAtR50S48bg #myeloidneoplasia #transplantation
Image from Blood Journals Portfolio (@BloodPortfolio)
1
30
1
87
12,606
Check out Cancer Center Director Dr. D. Neil Hayes, Program Director Dr. David Schwartz, and former UTHSC Trainee Dr. Oluchukwu Oluoha for their commentary published in the Journal of Clinical Oncology on personalized care in head and neck cancer. ascopubs.org/doi/full/10.120…
Image from UTHSC Center for Cancer Research (@UTHSC_Cancer)
Image from UTHSC Center for Cancer Research (@UTHSC_Cancer)
Image from UTHSC Center for Cancer Research (@UTHSC_Cancer)
3
1
10
942
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions | NEJM nejm.org/doi/full/10.1056/NE…
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions | NEJM

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions | NEJM

Amivantamab has been approved for the treatment of patients with advanced non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions who have had disease pro...

nejm.org
184
Patient first; person first - The Lancet Oncology thelancet.com/journals/lanon…
Patient first; person first

Patient first; person first

A cancer patient. A cancer case. Common terms, but ones that can have a great impact on patients and their mental health. By using disease-first language such as this, one can dehumanise the patient,...

thelancet.com
2
175
Oluchukwu Oluoha, MD retweeted
Science Magazine (@ScienceMagazine) profile picture
Science Magazine
@ScienceMagazine24 Sep 2023
In Science, researchers engineered #Cancer cells with and without specific chromosome abnormalities, showing how tumors rely on them for survival and clarifying the biological role of aneuploidy. Check out the study on #WorldCancerResearchDay: scim.ag/4cZ
Image from Science Magazine (@ScienceMagazine)
10
187
2
577
127,668
Oluchukwu Oluoha, MD retweeted
Forbes (@Forbes) profile picture
Forbes
@Forbes23 Sep 2023
"We don't live for money and titles...I think we live for love. We live for joy. We live for passion." Dominika Kulczyk, founder and president at Kulczyk Foundation, spoke to Forbes CEO @Mike_Federle about what drives her to make a difference at the #ForbesPhilanthropy Summit.
8
7
18
34,659
Oluchukwu Oluoha, MD retweeted
UTHSC Sickle Cell Disease (@UTHSC_SCD) profile picture
UTHSC Sickle Cell Disease@UTHSC_SCD23 Aug 2023
Congratulations to Dr. Kenneth Ataga for being nominated for the 2023 Health Care Heroes Award by the Memphis Business Journal!
1
3
138
Oluchukwu Oluoha, MD retweeted
Targeted Onc (@TargetedOnc) profile picture
Targeted Onc@TargetedOnc30 Aug 2023
According to data from the final OS analysis of the ExteNET trial, neratinib did not significantly improve overall survival vs placebo for patients with early-stage HER2+ breast cancer in the extended adjuvant setting. #bcsm ow.ly/7I2P50PFYOA

8-Year OS Similar Between Neratinib and Placebo in HER2+ Breast Cancer | Targeted Oncology -...

In an 8-year follow up analysis of patients on the ExteNET trial, researchers saw that overall survival was not significantly different to rates on placebo.

targetedonc.com
1
2
823
Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders loom.ly/Qq7n4m4
Image from Blood Journals Portfolio (@BloodPortfolio)
16
52
7,510
Oluchukwu Oluoha, MD retweeted
OncLive.com (@OncLive) profile picture
OncLive.com
@OncLive29 Jun 2023
Navigating Personalized Cancer Care by Mapping the Tumor. Learn how distinct tumor biomarkers within each tumor type can help inform your clinical decision-making and the treatment journey for your patients. bit.ly/4010x7F
Image from OncLive.com (@OncLive)
1
887
Oluchukwu Oluoha, MD retweeted
ASGCT (@ASGCTherapy) profile picture
ASGCT
@ASGCTherapy29 Jun 2023
Today, #FDA approved the first #genetherapy to treat adults with severe Hemophilia A, #Roctavian. Approximately 1 in 10,000 people have the blood clotting disorder. Read the statement from ASGCT President Jeffrey Chamberlain, PhD (@UW): asgct.org/publications/news/…
Image from ASGCT (@ASGCTherapy)
1
17
42
2,900
Oluchukwu Oluoha, MD retweeted
Amir Kaki, MD (@DrAmirKaki) profile picture
Amir Kaki, MD@DrAmirKaki27 May 2023
The ECP pivotal is in full swing. Albuquerque, Tucson, Missoula, Buffalo, Norfolk, and NYC officially on board. Great cases by the 🐅 and our graduating fellows Fola and Phil! Awesome colleagues visited and helped us through the cases. @DrTedSchreiber @tlalondemd on the assist – at Detroit, MI
Image from Amir Kaki, MD (@DrAmirKaki)
Image from Amir Kaki, MD (@DrAmirKaki)
Image from Amir Kaki, MD (@DrAmirKaki)
Image from Amir Kaki, MD (@DrAmirKaki)
9
8
1
84
16,283
Henry Ford Health 10th Annual Multidisciplinary Head and Neck Cancer Symposium
Image from Oluchukwu Oluoha, MD (@oluoha)
1
6
260
Load more